Praxis Precision Medicines

Cambridge, United States Founded: 2015 • Age: 11 yrs Listed
Therapies for brain disorders are developed by the company.

About Praxis Precision Medicines

Praxis Precision Medicines is a publicly listed company based in Cambridge (United States) founded in 2015. Therapies for brain disorders are developed by the company. Praxis Precision Medicines has raised $110 million across 1 funding round from investors including Blackstone, Citadel and Verition Fund Management. The company has 116 employees. Its chief executive, as recorded, is Marcio Souza. Its website praxismedicines.com draws about 36 thousand monthly visits. Praxis Precision Medicines offers products and services including Precision Therapies and Clinical Assets. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its legal entity is Praxis Precision Medicines, Inc. Its competitors include Kriya Therapeutics, Sana Biotechnology and PureTech Health; 3 of its 3 listed competitors have raised funding.

Company details

Praxis Precision Medicines was founded in 2015 and is headquartered in Cambridge, United States. Therapies targeting brain disorders are developed within the biotechnology sector. Key candidates include Prax-114 for mood disorders, Prax-994 for movement disorders such as epilepsy, Prax-222 and Prx-120 for genetic epilepsies, and Prax-562 for pain disorders. Operations focus on advancing these treatments through research and development. Leadership is provided by CEO and President Marcio Souza.

  • Headquarters Cambridge, United States
  • Employees 116
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website praxismedicines.com
  • Social LinkedIn Facebook Instagram
  • Legal Name Praxis Precision Medicines, Inc.
Operational Areas
Key Metrics
  • Net Profit
    -$303.27 M (USD)
    -65.88
    as on Dec 31, 2025
  • EBITDA
    -$326.06 M (USD)
    -63.19
    as on Dec 31, 2025
  • Total Equity Funding
    $110M (USD)

    in 1 rounds

  • Latest Funding Round
    $110M (USD), Series C

    May 2020

  • Investors
    Blackstone

    & 11 more

  • Employee Count
    116

Products & Services of Praxis Precision Medicines

Praxis Precision Medicines offers a comprehensive portfolio of products and services, including Precision Therapies and Clinical Assets.

Precision Therapies
Biopharmaceuticals

Develops treatments for CNS disorders based on genetic insights.

Clinical Assets
Therapeutic Development

Advances programs like EMBOLD for epilepsy treatment via genetics.

Funding Insights of Praxis Precision Medicines

Praxis Precision Medicines has successfully raised a total of $110M through 1 strategic funding round. The most recent funding activity was a Series C round of $110 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $110M
  • Total Rounds 1
  • Last Round Series C β€” $110M
  • First Round $110M

    (May 2020)

  • Investors Count 12

All 1 funding rounds of Praxis Precision Medicines with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
May 2020$110MSeries C–Eventide Funds
Valuation history

12 investors in total: 12 institutional.

Investors in Praxis Precision Medicines

Praxis Precision Medicines has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Blackstone, Citadel and Verition Fund Management.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Diversified investment management is provided across multiple asset classes.
1985blackstone.comNew York, United States
Private equity and venture capital fund focused on the healthcare sector
novoholdings.dkHellerup, Denmark
Biomedical innovations are transformed into therapies by Vida Ventures.
vidaventures.comBoston, United States
Early-stage startups are invested in by sector-agnostic VC fund.
irvinginvestors.comNew York, United States
Venture capital fund focused on biotechnology startups
avorocapital.comNew York, United States
Venture capital investments are provided by OCV Partners.
ocvpartners.comLos Angeles, United States
Eventide Mutual Funds is managed by Eventide Asset Management, offering investment solutions.
eventidefunds.comBoston, United States
Provider of investment & fund management services
2008verition.comGreenwich, United States
Manages alternative investments through equity, systematic, macro, and private strategies worldwide.
2014point72.comStamford, United States
Long, short, event-driven, and multiple strategies are employed by Citadel.
1990citadel.comChicago, United States
Premium access

Investor details for Praxis Precision Medicines

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Praxis Precision Medicines

58 people are tracked at Praxis Precision Medicines (34 in leadership, 6 in board & advisors, 18 in team); the tracked headcount is 116.

NameRoleGroup
Marcio Souza
CEO & PresidentLeadership
Louie B.
Director Clinical SupplyLeadership
Amber Roberts
Senior Director, Clinical QualityLeadership
Lyndsey Anderson
Associate DirectorLeadership
Tim Kelly
CFOLeadership
Alyssa Wyant
Chief Regulatory & Quality OfficerLeadership
Megan Sniecinski
Chief Business OfficerLeadership
Kelly McCue
Chief People OfficerLeadership
Saba Jafarpour
Associate Medical Director- Clinical DevelopmentLeadership
Toni C. Meadows
Associate Director, Data ManagementLeadership
Hong Sun
Senior Vice President, Head Of Clinical DevelopmentLeadership
Steven Petrou
Co-Founder & Chief Scientific OfficerLeadership
Kris Kahlig
VP Of Biology, Discovery SciencesLeadership
Karl Hansen
Chief Technical Operations OfficerLeadership
Vincent Amoruccio
Vice President, Head Of Data SciencesLeadership
Laura McIntyre
Associate Director, AccountingLeadership
Doris Neville
Executive Director, CMC Head Of Engineering And CommercializationLeadership
Maribel Hernandez
Vp, Head Of Clinical OperationsLeadership
Charmaine Manilay
Associate Director, Regulatory Writing And OperationsLeadership
Ida Licata
Head Of Business Operations OutsourcingLeadership

38 more people are available in the full profile.

Premium access

Complete people profiles for Praxis Precision Medicines

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Praxis Precision Medicines

Praxis Precision Medicines is a publicly listed company on the NASDAQ with ticker symbol PRAX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date16 Oct 2020
  • Listed onNASDAQ: PRAX
  • Listed entityPraxis Precision Medicines, Inc.
  • Exchange sectorHealth technology
  • ISINUS74006W2070
  • Share price$243.34 (-3.2% on the day) · 2026-10-13
  • Market capitalisation$6.79B
  • EPS (diluted, trailing year)$-12.94
  • Volume (last session)622,168

Financials of Praxis Precision Medicines

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025-$303.3M-$326.1M
2024$8.6M-$182.8M-$199.8M
2023$2.5M-$123.3M-$125.9M
2022-$214.0M-$213.8M
2021-$167.1M-$165.7M
Premium access

Detailed financial statements for Praxis Precision Medicines

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Praxis Precision Medicines

3 dated milestones of Praxis Precision Medicines across 5 years, from founding to its latest funding, stage changes and deals.

  1. Founded Praxis Precision Medicines is founded.
  2. Funding First funding round of $110.0M.
  3. IPO Lists on the stock exchange (IPO).

Competitors of Praxis Precision Medicines

Praxis Precision Medicines has 3 listed competitors in our database, 3 of them funded. They include Kriya Therapeutics, Sana Biotechnology and PureTech Health.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
kriyatherapeutics.com2012Redwood, United States$930.93M159
Developer of therapeutic solutions for the treatment of diabetes
sana.com2018Seattle, United States$821M328
Genetically engineered cell therapies are developed for multiple disorders.
puretechhealth.com2001Boston, United States$107M171
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
Premium access

Detailed competitors of Praxis Precision Medicines

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Praxis Precision Medicines

The website of Praxis Precision Medicines (praxismedicines.com) receives about 35.6K visits a month and ranks #1,244,570 among all websites worldwide, #1,572 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    35.6K

    ▲ 47.8% vs previous month

  • Unique visitors
    12.4K

    per month

  • Global rank
    #1,244,570

    among all websites

  • Category rank
    #1,572

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Praxis Precision Medicines. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
servier.us
100%
#2,050,491View details
paratekpharma.com
99%
4K#5,533,702View details
ensoma.com
99%
2.8K#4,644,561View details
pieris.com
99%
View details
zealandpharma.com
96%
25.2K#1,273,571View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 16 similar websites and full traffic analytics for Praxis Precision Medicines

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 16 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Neurology

3 companies that operate in the same segment as Praxis Precision Medicines (Neurology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
2013San Francisco, California, United StatesUSD 214.78 MUSD 21.05 M211
Developer of therapeutics for psychiatric and neurologic diseases
2002New York, New York, United StatesUSD 80.87 MUSD 250.31 M600
Biologics platform developed for intracellular delivery in rare diseases.
2016Boston, Massachusetts, United StatesUSD 175.25 MUSD 25.42 M183
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Praxis Precision Medicines

Premium access

Complete news archive for Praxis Precision Medicines

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Praxis Precision Medicines

Praxis Precision Medicines was founded in 2015 and raised its 1st funding round 5 years after it was founded.

Praxis Precision Medicines is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Marcio Souza is the CEO of Praxis Precision Medicines, as recorded in our data.

Praxis Precision Medicines is a funded company, having raised a total of $110M across 1 funding round to date. The company's 1st funding round was a Series C of $110M, raised on May 2020.

Praxis Precision Medicines has 116 employees.

Praxis Precision Medicines was founded in 2015 and is headquartered in Cambridge, United States. Therapies targeting brain disorders are developed within the biotechnology sector. Key candidates include Prax-114 for mood disorders, Prax-994 for movement disorders such as epilepsy, Prax-222 and Prx-120 for genetic epilepsies, and Prax-562 for pain disorders. Operations focus on advancing these treatments through research and development. Leadership is provided by CEO and President Marcio Souza.

Praxis Precision Medicines's top competitors include Sana Biotechnology, PureTech Health and Kriya Therapeutics.

Praxis Precision Medicines offers Precision Therapies and Clinical Assets.

Yes, Praxis Precision Medicines is publicly traded on NASDAQ under the ticker symbol PRAX.

Praxis Precision Medicines has 12 investors. Key investors include Blackstone, Citadel, Verition Fund Management, Novo Holdings, and Vida Ventures.

Praxis Precision Medicines operates through Praxis Precision Medicines, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available